Annual Accounts Payable
$7.14 M
-$15.37 M-68.27%
31 December 2023
Summary:
Rigel Pharmaceuticals annual accounts payable is currently $7.14 million, with the most recent change of -$15.37 million (-68.27%) on 31 December 2023. During the last 3 years, it has risen by +$3.44 million (+92.66%). RIGL annual accounts payable is now -68.27% below its all-time high of $22.51 million, reached on 31 December 2022.RIGL Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Payable
$3.81 M
-$2.31 M-37.77%
30 September 2024
Summary:
Rigel Pharmaceuticals quarterly accounts payable is currently $3.81 million, with the most recent change of -$2.31 million (-37.77%) on 30 September 2024. Over the past year, it has dropped by -$4.18 million (-52.31%). RIGL quarterly accounts payable is now -83.05% below its all-time high of $22.51 million, reached on 31 December 2022.RIGL Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RIGL Accounts Payable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -68.3% | -52.3% |
| 3 y3 years | +92.7% | +21.3% |
| 5 y5 years | +11.8% | +43.4% |
RIGL Accounts Payable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -68.3% | +92.7% | -83.0% | +77.0% |
| 5 y | 5 years | -68.3% | +92.7% | -83.0% | +125.9% |
| alltime | all time | -68.3% | +708.8% | -83.0% | +453.7% |
Rigel Pharmaceuticals Accounts Payable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $3.81 M(-37.8%) |
| June 2024 | - | $6.13 M(-33.9%) |
| Mar 2024 | - | $9.28 M(+29.9%) |
| Dec 2023 | $7.14 M(-68.3%) | $7.14 M(-10.7%) |
| Sept 2023 | - | $8.00 M(+52.7%) |
| June 2023 | - | $5.24 M(-16.8%) |
| Mar 2023 | - | $6.29 M(-72.0%) |
| Dec 2022 | $22.51 M(+493.1%) | $22.51 M(+727.2%) |
| Sept 2022 | - | $2.72 M(+26.3%) |
| June 2022 | - | $2.15 M(-53.3%) |
| Mar 2022 | - | $4.61 M(+21.6%) |
| Dec 2021 | $3.79 M(+2.4%) | $3.79 M(+20.7%) |
| Sept 2021 | - | $3.14 M(+86.1%) |
| June 2021 | - | $1.69 M(-66.8%) |
| Mar 2021 | - | $5.09 M(+37.4%) |
| Dec 2020 | $3.71 M(-10.7%) | $3.71 M(+62.4%) |
| Sept 2020 | - | $2.28 M(-33.1%) |
| June 2020 | - | $3.41 M(+54.7%) |
| Mar 2020 | - | $2.21 M(-46.8%) |
| Dec 2019 | $4.15 M(-35.0%) | $4.15 M(+56.0%) |
| Sept 2019 | - | $2.66 M(-29.5%) |
| June 2019 | - | $3.78 M(+220.4%) |
| Mar 2019 | - | $1.18 M(-81.6%) |
| Dec 2018 | $6.39 M(+142.5%) | $6.39 M(+142.0%) |
| Sept 2018 | - | $2.64 M(-21.0%) |
| June 2018 | - | $3.34 M(+27.4%) |
| Mar 2018 | - | $2.62 M(-0.5%) |
| Dec 2017 | $2.64 M(-52.6%) | $2.64 M(+20.2%) |
| Sept 2017 | - | $2.19 M(+6.1%) |
| June 2017 | - | $2.07 M(+75.4%) |
| Mar 2017 | - | $1.18 M(-78.8%) |
| Dec 2016 | $5.56 M(+101.3%) | $5.56 M(+266.5%) |
| Sept 2016 | - | $1.52 M(+0.8%) |
| June 2016 | - | $1.51 M(-37.9%) |
| Mar 2016 | - | $2.42 M(-12.3%) |
| Dec 2015 | $2.76 M(+71.3%) | $2.76 M(+301.0%) |
| Sept 2015 | - | $689.00 K(-37.1%) |
| June 2015 | - | $1.10 M(-3.5%) |
| Mar 2015 | - | $1.14 M(-29.6%) |
| Dec 2014 | $1.61 M(-58.7%) | $1.61 M(+58.4%) |
| Sept 2014 | - | $1.02 M(-46.3%) |
| June 2014 | - | $1.90 M(+63.9%) |
| Mar 2014 | - | $1.16 M(-70.4%) |
| Dec 2013 | $3.90 M(+130.0%) | $3.90 M(+280.8%) |
| Sept 2013 | - | $1.02 M(-51.7%) |
| June 2013 | - | $2.12 M(-0.8%) |
| Mar 2013 | - | $2.14 M(+26.0%) |
| Dec 2012 | $1.70 M | $1.70 M(+22.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2012 | - | $1.39 M(-27.4%) |
| June 2012 | - | $1.91 M(-0.5%) |
| Mar 2012 | - | $1.92 M(+23.5%) |
| Dec 2011 | $1.56 M(+10.9%) | $1.56 M(+22.0%) |
| Sept 2011 | - | $1.27 M(-12.7%) |
| June 2011 | - | $1.46 M(+14.9%) |
| Mar 2011 | - | $1.27 M(-9.3%) |
| Dec 2010 | $1.40 M(-55.5%) | $1.40 M(-54.0%) |
| June 2010 | - | $3.05 M(-17.6%) |
| Mar 2010 | - | $3.70 M(+17.3%) |
| Dec 2009 | $3.15 M(-47.3%) | $3.15 M(-10.0%) |
| Sept 2009 | - | $3.50 M(-22.1%) |
| June 2009 | - | $4.50 M(-33.8%) |
| Mar 2009 | - | $6.79 M(+13.5%) |
| Dec 2008 | $5.98 M(+38.5%) | $5.98 M(+23.4%) |
| Sept 2008 | - | $4.85 M(+60.6%) |
| June 2008 | - | $3.02 M(-15.8%) |
| Mar 2008 | - | $3.59 M(-16.9%) |
| Dec 2007 | $4.32 M(+120.7%) | $4.32 M(+72.0%) |
| Sept 2007 | - | $2.51 M(+6.2%) |
| June 2007 | - | $2.37 M(+35.7%) |
| Mar 2007 | - | $1.74 M(-10.9%) |
| Dec 2006 | $1.96 M(-21.6%) | $1.96 M(+34.8%) |
| Sept 2006 | - | $1.45 M(-6.0%) |
| June 2006 | - | $1.54 M(-39.1%) |
| Mar 2006 | - | $2.54 M(+1.6%) |
| Dec 2005 | $2.50 M(+28.4%) | $2.50 M(-8.8%) |
| Sept 2005 | - | $2.74 M(-14.0%) |
| June 2005 | - | $3.19 M(+37.1%) |
| Mar 2005 | - | $2.32 M(+19.4%) |
| Dec 2004 | $1.95 M(+41.1%) | $1.95 M(-21.7%) |
| Sept 2004 | - | $2.48 M(-2.4%) |
| June 2004 | - | $2.54 M(+81.6%) |
| Mar 2004 | - | $1.40 M(+1.7%) |
| Dec 2003 | $1.38 M(-60.2%) | $1.38 M(+2.5%) |
| Sept 2003 | - | $1.34 M(+30.4%) |
| June 2003 | - | $1.03 M(-40.0%) |
| Mar 2003 | - | $1.72 M(-50.3%) |
| Dec 2002 | $3.46 M(+77.3%) | $3.46 M(-31.1%) |
| Sept 2002 | - | $5.02 M(+85.6%) |
| June 2002 | - | $2.71 M(-36.8%) |
| Mar 2002 | - | $4.28 M(+119.4%) |
| Dec 2001 | $1.95 M(+48.6%) | $1.95 M(+162.0%) |
| Sept 2001 | - | $745.00 K(-45.0%) |
| June 2001 | - | $1.35 M(+7.7%) |
| Mar 2001 | - | $1.26 M(-4.3%) |
| Dec 2000 | $1.31 M(+48.8%) | $1.31 M |
| Dec 1999 | $883.00 K | - |
FAQ
- What is Rigel Pharmaceuticals annual accounts payable?
- What is the all time high annual accounts payable for Rigel Pharmaceuticals?
- What is Rigel Pharmaceuticals annual accounts payable year-on-year change?
- What is Rigel Pharmaceuticals quarterly accounts payable?
- What is the all time high quarterly accounts payable for Rigel Pharmaceuticals?
- What is Rigel Pharmaceuticals quarterly accounts payable year-on-year change?
What is Rigel Pharmaceuticals annual accounts payable?
The current annual accounts payable of RIGL is $7.14 M
What is the all time high annual accounts payable for Rigel Pharmaceuticals?
Rigel Pharmaceuticals all-time high annual accounts payable is $22.51 M
What is Rigel Pharmaceuticals annual accounts payable year-on-year change?
Over the past year, RIGL annual accounts payable has changed by -$15.37 M (-68.27%)
What is Rigel Pharmaceuticals quarterly accounts payable?
The current quarterly accounts payable of RIGL is $3.81 M
What is the all time high quarterly accounts payable for Rigel Pharmaceuticals?
Rigel Pharmaceuticals all-time high quarterly accounts payable is $22.51 M
What is Rigel Pharmaceuticals quarterly accounts payable year-on-year change?
Over the past year, RIGL quarterly accounts payable has changed by -$4.18 M (-52.31%)